|
1.
|
2025/05
|
|
Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study
|
|
2.
|
2025/04/21
|
|
Transitional changes in medication-initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes-A hospital-based cohort study in Japan
|
|
3.
|
2025/04/10
|
|
Maintaining kidney health in aging societies: a JSN and ERA call to action
|
|
4.
|
2025/03/25
|
|
Establishing Cross-Specialty Expert Consensus on the Optimal Management of Hyperkalemia in Patients With Heart Failure and Chronic Kidney Disease
|
|
5.
|
2025/02/20
|
|
Efficacy and safety of patiromer for hyperkalemia: a randomized, placebo-controlled phase 3 study
|
|
6.
|
2025/02/06
|
|
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
|
|
7.
|
2025/02
|
|
Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study
|
|
8.
|
2025/02
|
|
Oral microbiome alpha diversity and all-cause, cardiovascular, and non-cardiovascular mortality in US adults: Evidence from the NHANES 2009-2019
|
|
9.
|
2025/01/15
|
|
Comparative analysis of kidney function prediction: traditional statistical methods vs. deep learning techniques
|
|
10.
|
2025/01
|
|
The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes
|
|
11.
|
2024/12/16
|
|
The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese non-diabetic patients
|
|
12.
|
2024/12/01
|
|
Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial
|
|
13.
|
2024/11/24
|
|
Efficacy and safety of patiromer for non-dialysis and dialysis patients with hyperkalemia: the randomized, placebo-controlled and long-term study
|
|
14.
|
2024/11/11
|
|
Association between proteinuria and mineral metabolism disorders in chronic kidney disease: the Japan chronic kidney disease database extension (J-CKD-DB-Ex)
|
|
15.
|
2024/11/09
|
|
The Role of Mitochondria in Diabetic Kidney Disease and Potential Therapeutic Targets
|
|
16.
|
2024/11/02
|
|
ASK-1 activation exacerbates kidney dysfunction via increment of glomerular permeability and accelerates cellular aging in diabetic kidney disease model mice
|
|
17.
|
2024/11
|
|
Effects of Beraprost on Intestinal Microcirculation and Barrier Function in a Mouse Model of Renal Failure. inpress
|
|
18.
|
2024/10/25
|
|
The Change in Public Perception and Knowledge Acquisition Methods of Chronic Kidney Disease Among General Population in Okayama Prefecture, Japan
|
|
19.
|
2024/09/01
|
|
Gross Hematuria after the COVID-19 mRNA Vaccination: Nationwide Multicenter Prospective Cohort Study in Japan
|
|
20.
|
2024/09
|
|
Evaluation of glomerular hemodynamic changes by sodium-glucose-transporter 2 inhibition in type 2 diabetic rats using in vivo imaging
|
|
21.
|
2024/09
|
|
Guidelines for clinical evaluation of chronic kidney disease in early stages : AMED research on regulatory science of pharmaceuticals and medical devices.
|
|
22.
|
2024/09
|
|
Treatment of chronic kidney disease in older populations
|
|
23.
|
2024/08
|
|
Association of serum magnesium levels with renal prognosis in patients with chronic kidney disease
|
|
24.
|
2024/07
|
|
Factors affecting the sodium-glucose cotransporter 2 inhibitors-related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: The Japan Chronic Kidney Disease Database.
|
|
25.
|
2024/06
|
|
Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY
|
|
26.
|
2024/05/30
|
|
Kidney outcomes of SGLT2 inhibitors among older patients with diabetic kidney disease in real-world clinical practice: the Japan Chronic Kidney Disease Database Ex
|
|
27.
|
2024/05/20
|
|
Evaluating the associations between compliance with CKD guideline component metrics and renal outcomes.
|
|
28.
|
2024/05/08
|
|
Factors affecting the sodium-glucose cotransporter2 inhibitors-related initial decline in glomerular filtration rate
and its possible effect on kidney outcome in chronic kidneydisease with type 2 diabetes: The Japan Chronic Kidney Disease Database
|
|
29.
|
2024/04/11
|
|
Development of a prognostic risk score to predict early mortality in incident elderly Japanese hemodialysis patients.
|
|
30.
|
2024/03/26
|
|
Multicenter randomized controlled trial of intensive uric acid lowering therapy for CKD patients with hyperuricemia: TARGET-UA
|
|
31.
|
2024/03/13
|
|
Mathematical expansion and clinical application of chronic kidney disease stage as vector field
|
|
32.
|
2024/02
|
|
Oxidative stress and the role of redox signalling in chronic kidney disease
|
|
33.
|
2024/01/18
|
|
New marker for chronic kidney disease progression and mortality in medical-word virtual space.
|
|
34.
|
2024/01/09
|
|
A case series of Fabry diseases with CKD in Japan.
|
|
35.
|
2024/01
|
|
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy
|
|
36.
|
2023/12/19
|
|
IL-1β may be an indicator of peritoneal deterioration after healing of peritoneal dialysis-associated peritonitis
|
|
37.
|
2023/12/13
|
|
Lifestyle factors associated with a rapid decline in the estimated glomerular filtration rate over two years in older adults with type 2 diabetes-Evidence from a large national database in Japan
|
|
38.
|
2023/10/23
|
|
Kidney outcomes associated with haematuria and proteinuria trajectories among patients with IgA nephropathy in real-world clinical practice: The Japan Chronic Kidney Disease Database
|
|
39.
|
2023/10/01
|
|
Insights into the regulation of glomerular filtration rate by the Keap1-Nrf2 pathway
|
|
40.
|
2023/10
|
|
Insights into the Regulation of GFR by the Keap1-Nrf2 Pathway.
|
|
41.
|
2023/09
|
|
Activation of the inflammasome drives peritoneal deterioration in a mouse model of peritoneal fibrosis
|
|
42.
|
2023/09
|
|
Activation of the inflammasome drives peritoneal deterioration in a mouse model of peritoneal fibrosis.
|
|
43.
|
2023/07/19
|
|
eGFR slope as a surrogate endpoint for clinical study in early stage of chronic kidney disease: from The Japan Chronic Kidney Disease Database
|
|
44.
|
2023/07/18
|
|
Relationship between the lower limit of systolic blood pressure target and kidney function decline in advanced chronic kidney disease: an instrumental variable analysis from the REACH-J CKD cohort study
|
|
45.
|
2023/06
|
|
Dapagliflozin and Anemia in Patients with Chronic Kidney Disease
|
|
46.
|
2023/06
|
|
Effect of the Diabetic Nephropathy Aggravation Prevention Program on medical visit behavior in individuals under the municipal national health insurance
|
|
47.
|
2023/06
|
|
The Impact of Potassium Binders on Mortality in Patients with Hyperkalemia: A Single-Center Study
|
|
48.
|
2023/05/04
|
|
Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study
|
|
49.
|
2023/05
|
|
Current status of the rapid decline in renal function due to diabetes mellitus and its associated factors: analysis using the National Database of Health Checkups in Japan
|
|
50.
|
2023/02/09
|
|
Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study
|
|
51.
|
2023/02
|
|
Genome-wide association study of the risk of chronic kidney disease and kidney-related traits in the Japanese population: J-Kidney-Biobank
|
|
52.
|
2023/02
|
|
The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial
|
|
53.
|
2023/01/01
|
|
A Randomized Controlled Trial of Whole-Body Vibration on Gait Ability and Balance among Older Hemodialysis Patients
|
|
54.
|
2023/01
|
|
Machine-learning-based Web system for the prediction of chronic kidney disease progression and mortality
|
|
55.
|
2023
|
|
The deficient of eNOS-NO pathway exacerbates kidney dysfunction
via inflammasome activation in diabetic kidney disease
|
|
56.
|
2022/07
|
|
Analysis of inflammatory cytokines and estimated glomerular filtration rate decline in Japanese patients with diabetic kidney disease: a pilot study.
|
|
57.
|
2022/04
|
|
Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan.
|
|
58.
|
2022/03/23
|
|
A case of pleuroperitoneal communication during long-term steroid therapy for dermatomyositis
|
|
59.
|
2022/03
|
|
Kidney vascular congestion exacerbates acute kidney injury in mice.
|
|
60.
|
2022/02/24
|
|
Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies.
|
|
61.
|
2022/02/01
|
|
Evaluation of Neutrophil Dynamics Change by Protective Effect of Tadalafil After Renal Ischemia/Reperfusion Using In Vivo Real-time Imaging.
|
|
62.
|
2022/01/06
|
|
Trans-ethnic Mendelian-randomization study reveals causal relationships between cardiometabolic factors and chronic kidney disease.
|
|
63.
|
2022/01
|
|
Statement of the Asian Hypertension Society Network: the Okinawa Declaration on the unity of hypertension societies in Asian countries and regions to overcome hypertension and hypertension-related diseases.
|
|
64.
|
2021/12
|
|
Physical functioning in patients with chronic kidney disease stage G3b-5 in Japan: The reach-J CKD cohort study.
|
|
65.
|
2021/11
|
|
Dipeptidyl peptidase-4 inhibitor linagliptin reduces urinary albumin excretion through the protection of glomerular endothelial function
|
|
66.
|
2021/11
|
|
Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database.
|
|
67.
|
2021/10/05
|
|
Prescription Patterns of Antimicrobial Agents for Upper Respiratory
Tract Infections in Patients Visiting the Emergency Department of
Kawasaki Medical School Hospital: A Descriptive Study
|
|
68.
|
2021/10
|
|
Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study.
|
|
69.
|
2021/09
|
|
Clinical and histological features in pediatric and adolescent/young adult patients with renal disease: a cross-sectional analysis of the Japan Renal Biopsy Registry (J-RBR)
|
|
70.
|
2021/09
|
|
Nationwide survey of the coronavirus disease 2019 prevention and treatment systems for kidney disease patients: a study of Japanese Society of Nephrology-certified educational facilities.
|
|
71.
|
2021/08/27
|
|
Endothelial Dysfunction Accelerates Impairment of Mitochondrial Function in Ageing Kidneys via Inflammasome Activation
|
|
72.
|
2021/08/17
|
|
Efficacy of the Self-management Support System DialBetesPlus for Diabetic Kidney Disease: Protocol for a Randomized Controlled Trial.
|
|
73.
|
2021/08/02
|
|
Prologue: Special Spotlight Issue on Japan.
|
|
74.
|
2021/08
|
|
A rare case of amyloid light-chain amyloidosis with bilateral perirenal hematoma shortly after initiation of peritoneal dialysis.
|
|
75.
|
2021/08
|
|
Comparison of annual eGFR decline among primary kidney diseases in patients with CKD G3b-5: results from a REACH-J CKD cohort study.
|
|
76.
|
2021/08
|
|
Toward the development of a vibrant, super-aged society: The future of medicine and society in Japan.
|
|
77.
|
2021/07/14
|
|
Case reports of pregnancies complicated with kidney disease and their fetal prognosis
|
|
78.
|
2021/06/04
|
|
Dual disruption of eNOS and ApoE gene accelerates kidney fibrosis and senescence after injury
|
|
79.
|
2021/06
|
|
Renal cell carcinoma sharply captured by imaging technology at an early stage in a hemodialysis patient: Usefulness of noninvasive monochrome superb microvascular imaging
|
|
80.
|
2021/05/11
|
|
Effect of zinc deficiency on chronic kidney disease progression and effect modification by hypoalbuminemia.
|
|
81.
|
2021/05
|
|
Incidence and factors associated with prescribing renin-angiotensin-system inhibitors in adult idiopathic nephrotic syndrome: A nationwide cohort study.
|
|
82.
|
2021/04/23
|
|
Proteinuria changes in kidney disease patients with clinical remission during the COVID-19 pandemic.
|
|
83.
|
2021/04/17
|
|
SH3BP2 Deficiency Ameliorates Murine Systemic Lupus Erythematosus.
|
|
84.
|
2021/04/12
|
|
International Society of Nephrology Global Kidney Health Atlas: structures, organization and services for the management of kidney failure in North and East Asia.
|
|
85.
|
2021/01/19
|
|
Cardiovascular and Renal Outcomes Associated With Hyperkalemia in Chronic Kidney Disease: A Hospital-Based Cohort Study.
|
|
86.
|
2021
|
|
Infection prevention measures for patients undergoing hemodialysis during the COVID-19 pandemic in Japan: a nationwide questionnaire survey.
|
|
87.
|
2020/12/24
|
|
Drastic change in protein intake may cause a rapid decline of residual renal function after initiation of peritoneal dialysis.
|
|
88.
|
2020/12/13
|
|
Glomerular Classification Using Convolutional Neural Networks Based on Defined Annotation Criteria and Concordance Evaluation Among Clinicians.
|
|
89.
|
2020/12/07
|
|
Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.
|
|
90.
|
2020/12
|
|
Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose-response, phase 2/3 study.
|
|
91.
|
2020/12
|
|
Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial
|
|
92.
|
2020/11/03
|
|
Association of Arterial Stiffness With Kidney Function Among Adults Without Chronic Kidney Disease.
|
|
93.
|
2020/11/01
|
|
Non-purine selective xanthine oxidase inhibitor ameliorates glomerular endothelial injury in InsAkita diabetic mice.
|
|
94.
|
2020/10/24
|
|
A phase 3 multicenter open-label maintenance study to investigate the long-term safety of sodium zirconium cyclosilicate in Japanese subjects with hyperkalemia.
|
|
95.
|
2020/10/17
|
|
Clinical and Economic Burden of Hyperkalemia: A Nationwide Hospital-Based Cohort Study in Japan.
|
|
96.
|
2020/10/15
|
|
Prevalences of hyperuricemia and electrolyte abnormalities in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB)
|
|
97.
|
2020/10/08
|
|
Dapagliflozin in Patients with Chronic Kidney Disease.
|
|
98.
|
2020/10
|
|
Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS).
|
|
99.
|
2020/10
|
|
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
|
|
100.
|
2020/09
|
|
A nationwide cross-sectional analysis of thrombotic microangiopathy in the Japan Renal Biopsy Registry (J-RBR)
|
|
101.
|
2020/07/20
|
|
Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB).
|
|
102.
|
2020/06
|
|
Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS)
|
|
103.
|
2020/05/29
|
|
Application of explainable ensemble artificial intelligence model to categorization of hemodialysis-patient and treatment using nationwide-real-world data in Japan.
|
|
104.
|
2020/05/01
|
|
Klotho is a novel therapeutic target in peritoneal fibrosis via Wnt signaling inhibition.
|
|
105.
|
2020/05
|
|
Dialysis Care and Dialysis Funding in Asia.
|
|
106.
|
2020/04/30
|
|
J-CKD-DB: a nationwide multicentre electronic health record-based chronic kidney disease database in Japan.
|
|
107.
|
2020/03
|
|
Conditions, pathogenesis, and progression of diabetic kidney disease and early decliner in Japan.
|
|
108.
|
2020/02/01
|
|
Hypertension with chronic kidney disease
|
|
109.
|
2020/01
|
|
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors and underlying mechanisms.
|
|
110.
|
2019/11
|
|
Bardoxolone methyl analog attenuates proteinuria-induced tubular damage by modulating mitochondrial function.
|
|
111.
|
2019/11
|
|
New measures against chronic kidney diseases in Japan since 2018.
|
|
112.
|
2019/10
|
|
JSH Statement: Asahikawa declaration in promotion of diversity by the Japanese society of hypertension-the JSH Asahikawa declaration.
|
|
113.
|
2019/09
|
|
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019).
|
|
114.
|
2019/07
|
|
Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging.
|
|
115.
|
2019/07
|
|
Management of high blood with renal disease
|
|
116.
|
2019/06
|
|
JSH Statement: Kyoto declaration on hypertension research in Asia.
|
|
117.
|
2019/05/30
|
|
Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan.
|
|
118.
|
2019/05
|
|
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
|
|
119.
|
2019/04
|
|
Sh3bp2 Gain-Of-Function Mutation Ameliorates Lupus Phenotypes in B6.MRL-Faslpr Mice.
|
|
120.
|
2019/01
|
|
5-Aminolevulinic acid exerts renoprotective effect via Nrf2 activation in murine rhabdomyolysis-induced acute kidney injury.
|
|
121.
|
2019/01
|
|
Essential points from Evidence-based Clinical Practice Guidelines for Chronic Kidney Disease 2018.
|
|
122.
|
2018/12
|
|
Guidelines for clinical evaluation of chronic kidney disease : AMED research on regulatory science of pharmaceuticals and medical devices.
|
|
123.
|
2018/12
|
|
Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study.
|
|
124.
|
2018/12
|
|
The Japanese Society of Hypertension-Digest of plan for the future.
|
|
125.
|
2018/10/03
|
|
The eNOS-NO pathway attenuates kidney dysfunction via suppression of inflammasome activation in aldosterone-induced renal injury model mice.
|
|
126.
|
2018/10
|
|
The Japanese clinical practice guideline for acute kidney injury 2016..
|
|
127.
|
2018/09
|
|
Observation period for changes in proteinuria and risk prediction of end-stage renal disease in general population.
|
|
128.
|
2018/08
|
|
The Japanese Clinical Practice Guideline for acute kidney injury 2016.
|
|
129.
|
2018/07
|
|
Disease burden and challenges of chronic kidney disease in North and East Asia.
|
|
130.
|
2018/04
|
|
A nationwide prospective cohort study of patients with advanced chronic kidney disease in Japan: The Reach-J CKD cohort study.
|
|
131.
|
2018/04
|
|
Importance of glomerular filtration rate change as surrogate endpoint for the future incidence of end-stage renal disease in general Japanese population: community-based cohort study.
|
|
132.
|
2018/02
|
|
The Sendai declaration for the eradication of kidney disease.
|
|
133.
|
2018/01
|
|
Proteinuria in neuronal intranuclear inclusion disease
|
|
134.
|
2017/08
|
|
Infiltration of M1, but not M2, macrophages is impaired after unilateral ureter obstruction in Nrf2-deficient mice.
|
|
135.
|
2017/06
|
|
Colchicine attenuates renal fibrosis in a murine unilateral ureteral obstruction model.
|
|
136.
|
2017/06
|
|
Restricted nutrition-induced low birth weight, low number of nephrons and glomerular mesangium injury in Japanese quail.
|
|
137.
|
2017/03
|
|
Acute improvement of endothelial functions after oral ingestion of isohumulones, bitter components of beer
|
|
138.
|
2016/12
|
|
Concurrent Lateral Meniscal Repair with Anterior Cruciate Ligament Reconstruction Induces the Extrusion of the Lateral Meniscus: Assessments of Magnetic Resonance Images.
|
|
139.
|
2016/11
|
|
Building and Challenge for multicenter clinical database with hospital information system and MCDRS -Comprehensive clinical database for chronic kidney disease(CKD)in Japan(J-CKD-DB).
|
|
140.
|
2016/11
|
|
Cohort maker:a novel data management system for cohort studies.
|
|
141.
|
2016/10
|
|
Klotho attenuates renal hypertrophy and glomerular injury in Ins2Akita diabetic mice.
|
|
142.
|
2016/09
|
|
[113th Scientific Meeting of the Japanese Society of Internal Medicine: Symposium: Insight into the Mechanism of Diseases on New Perspective Arising in Internal Medicine: From Epigenetics to Organ Associations: Introduction]
|
|
143.
|
2016/08
|
|
A Case of Copper Deficiency-Induced Pancytopenia With Maintenance Hemodialysis Outpatient Treated With Polaprezinc.
|
|
144.
|
2016/06
|
|
The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial.
|
|
145.
|
2016/05/23
|
|
Feasibility of fluorescence energy transfer system for imaging the renoprotective effects of aliskiren in diabetic mice.
|
|
146.
|
2016/02
|
|
Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis.
|
|
147.
|
2016/01
|
|
Activation of endothelial NAD(P)H oxidase accelerates early glomerular injury in diabetic mice.
|
|
148.
|
2015/12
|
|
Severe hyperkalemia following ileostomy not colostomy in a patient undergoing chronic hemodialysis
|
|
149.
|
2015/09
|
|
Excess aldosterone is a critical danger signal for inflammasome activation in the development of renal fibrosis in mice.
|
|
150.
|
2015/09
|
|
Relationship between vascular function indexes, renal arteriolosclerosis, and renal clinical outcomes in chronic kidney disease.
|
|
151.
|
2015/08
|
|
Deficiency of endothelial nitric oxide signaling pathway exacerbates peritoneal fibrosis in mice.
|
|
152.
|
2015/05
|
|
Combination Irbesartan/Amlodipine versus Irbesartan/Cilnidipine for
Attenuation of Albuminuria in Rats with Streptozotocin-Induced Diabetic
Nephropathy
|
|
153.
|
2015/04
|
|
Massive cystic degeneration of a uterine leiomyoma in a patient with autosomal dominant polycystic kidney disease.
|
|
154.
|
2015/03
|
|
Differential effectiveness of ARB plus CCB therapy and high-dose ARB therapy in high-risk elderly hypertensive patients: subanalysis of the OSCAR study
|
|
155.
|
2015
|
|
[Aging and renal fibrosis]
|
|
156.
|
2014/12
|
|
Nuclear Factor Erythroid 2-Related Factor 2 is Activated by Rosuvastatin via p21cip1 Upregulation in Endothelial Cells
|
|
157.
|
2014/10
|
|
Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial.
|
|
158.
|
2014/07
|
|
Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in Renin-Angiotensin System (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics TreatMent with RAS inhibitOrs in a Chronic Kidney Disease Hypertensive Population) study.
|
|
159.
|
2014/05/10
|
|
［Acute kidney injury: progress in diagnosis and treatments. Topics: IV. Pathophysiology and treatments; 4. Association of CKD and acute kidney injury］
|
|
160.
|
2014/04
|
|
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014).
|
|
161.
|
2014/02
|
|
Angiotensin II Regulates Islet Microcirculation and Insulin Secretion in Mice.
|
|
162.
|
2014
|
|
Hypertension promotes islet morphological changes with vascular injury on pre-diabetic status in SHRsp rats.
|
|
163.
|
2013/08
|
|
Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version : JSN, JRS, and JCS Joint Working Group.
|
|
164.
|
2013/08
|
|
Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version : JSN, JRS, and JCS Joint Working Group.
|
|
165.
|
2013/06
|
|
Maintenance of endothelial guanosine triphosphate cyclohydrolase I ameliorates diabetic nephropathy.
|
|
166.
|
2013/04
|
|
Erythropoietin-producing tubercle granuloma in a hemodialysis patient.
|
|
167.
|
2013/04
|
|
Japan Renal Biopsy Registry and Japan Kidney Disease Registry: Committee Report for 2009 and 2010
|
|
168.
|
2013/04
|
|
Selective estrogen receptor modulation attenuates proteinuria-induced renal tubular damage by modulating mitochondrial oxidative status.
|
|
169.
|
2013/03
|
|
Angiostatin production increases in response to decreased nitric oxide in aging rat kidney.
|
|
170.
|
2013/02
|
|
GFR estimation using standardized serum cystatin C in Japan
|
|
171.
|
2012/12
|
|
Establishment of a blood purification system for renal failure rats using small-size dialyzer membranes.
|
|
172.
|
2012/12
|
|
Klotho protects against mouse renal fibrosis by inhibiting Wnt signaling.
|
|
173.
|
2012/12
|
|
Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR).
|
|
174.
|
2012/10
|
|
Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
|
|
175.
|
2012/08
|
|
[Internal medicine and neurological disease: progress in diagnosis and treatment. Topics: IV. Chronic kidney disease (CKD) and cerebrovascular diseases]
|
|
176.
|
2012/08
|
|
Tacrolimus Induces Glomerular Injury via Endothelial Dysfunction Caused by Reactive Oxygen Species and Inflammatory Change.
|
|
177.
|
2012/06
|
|
Endothelial dysfunction promotes the transition from compensatory renal hypertrophy to kidney injury after unilateral nephrectomy in mice.
|
|
178.
|
2012/05
|
|
[Chronic kidney disease (CKD)--recent progress. Topics: VI. Chronic kidney disease (CKD) and associated disorders: 9. Kidney and senescence]
|
|
179.
|
2012/03
|
|
Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity.
|
|
180.
|
2012/03
|
|
Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: a placebo-controlled double-blind parallel-group study
|
|
181.
|
2012
|
|
[Guidelines for iodinated contrast in a patient with CKD 2012]
|
|
182.
|
2012
|
|
Chronic Kidney Disease, Dyslipidemia, and Atherosclerosis.
|
|
183.
|
2011/08
|
|
Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria.
|
|
184.
|
2011/04
|
|
Overexpression of klotho protein modulates uninephrectomy-induced compensatory renal hypertrophy by suppressing IGF-I signals.
|
|
185.
|
2011/02
|
|
Mitochondrial damage-induced impairment of angiogenesis in the aging rat kidney.
|
|
186.
|
2011
|
|
A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy.
|
|
187.
|
2011
|
|
Comparison of Combination Therapy of Olmesartan plus Azelnidipine or Hydrochlorothiazide on Renal and Vascular Damage in SHR/NDmcr-cp Rats.
|
|
188.
|
2010/12
|
|
Erythropoietin enhances hydrogen peroxide-mediated dilatation of canine coronary collateral arterioles during myocardial ischemia in dogs in vivo
|
|
189.
|
2010/11
|
|
[Alterations of mesangial cell and matrix]
|
|
190.
|
2010/11
|
|
Histopathological manifestations of membranoproliferative glomerulonephritis and glomerular expression of plasmalemmal vesicle-associated protein-1 in a patient with polycythemia vera
|
|
191.
|
2010/09
|
|
Deterioration of glomerular endothelial surface layer induced by oxidative stress is implicated in altered permeability of macromolecules in Zucker fatty rats.
|
|
192.
|
2010/09
|
|
Renal denervation reduces glomerular injury by suppressing NAD(P)H oxidase activity in Dahl salt-sensitive rats.
|
|
193.
|
2010/07
|
|
Clear Correlation of Tetrahydrobiopterin with Nitric Oxide Bioavailability in Continuous Ambulatory Peritoneal Dialysis
|
|
194.
|
2010/05
|
|
Involvement of the renin-angiotensin system in the development of vascular damage in a rat model of arthritis: effect of angiotensin receptor blockers.
|
|
195.
|
2010/02
|
|
In vivo visualization of glomerular microcirculation and hyperfiltration in streptozotocin-induced diabetic rats.
|
|
196.
|
2010/02
|
|
Telmisartan improves endothelial dysfunction and renal autoregulation in Dahl salt-sensitive rats
|
|
197.
|
2010
|
|
Oxidative stress in diabetic nephropathy.
|
|
198.
|
2009/12
|
|
Azelnidipine exerts renoprotective effects by improvement of renal microcirculation in angiotensin II infusion rats.
|
|
199.
|
2009/12
|
|
Renal protective effect of RAAS blockade across the renal continuum, with a review of the efficacy and safety of valsartan.
|
|
200.
|
2009/10
|
|
Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy.
|
|
201.
|
2009/09
|
|
Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial
|
|
202.
|
2009/09
|
|
Reactive oxygen species mediate compensatory glomerular hypertrophy in rat uninephrectomized kidney
|
|
203.
|
2009/06
|
|
Revised equations for estimated GFR from serum creatinine in Japan
|
|
204.
|
2009/06
|
|
Zinc deficiency anemia and effects of zinc therapy in maintenance hemodialysis patients.
|
|
205.
|
2009/05
|
|
High dietary protein intake induces endothelial dysfunction in uninephrectomized rats
|
|
206.
|
2009/04
|
|
C/EBP-beta modulates transcription of tubulointerstitial nephritis antigen in obstructive uropathy.
|
|
207.
|
2009/03
|
|
Oral adsorbent AST-120 ameliorates endothelial dysfunction independent of renal function in rats with subtotal nephrectomy
|
|
208.
|
2009/02
|
|
Simple sampling strategy for measuring inulin renal clearance
|
|
209.
|
2009/01
|
|
Direct Measurement of Nitric Oxide Concentration in CAPD Dialysate
|
|
210.
|
2009/01
|
|
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)
|
|
211.
|
2008/12
|
|
Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy
|
|
212.
|
2008/12
|
|
Rap1b GTPase ameliorates glucose-induced mitochondrial dysfunction
|
|
213.
|
2008/09
|
|
[Molecular pathogenesis of chronic kidney disease]
|
|
214.
|
2008/04
|
|
Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy.
|
|
215.
|
2008/04
|
|
Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet.
|
|
216.
|
2008/03/10
|
|
[Physiopathology and treatment of diabetic nephropathy]
|
|
217.
|
2008/02
|
|
Olmesartan ameliorates progressive glomerular injury in subtotal nephrectomized rats through suppression of superoxide production.
|
|
218.
|
2008
|
|
[Therapeutic effects of RAS inhibitor in IgA nephropathy]
|
|
219.
|
2008
|
|
Abdominal pain as the initial presentation of Takayasu arteritis.
|
|
220.
|
2008
|
|
Co-occurrence of poststreptococcal reactive arthritis and acute glomerulonephritis.
|
|
221.
|
2008
|
|
Efficacy of low-dose tacrolimus added to methotrexate in patients with rheumatoid arthritis in Japan: a retrospective study.
|
|
222.
|
2007/10
|
|
Olmesartan ameliorates renovascular injury and oxidative stress in Zucker obese rats enhanced by dietary protein.
|
|
223.
|
2007/10
|
|
Pioglitazone ameliorates endothelial dysfunction in obese rats with nephropathy.
|
|
224.
|
2007/06
|
|
Fluvastatin reverses endothelial dysfunction and increased vascular oxidative stress in rat adjuvant-induced arthritis.
|
|
225.
|
2007/03
|
|
A requirement of FANCL and FANCD2 monoubiquitination in DNA repair
|
|
226.
|
2007/03
|
|
Enhanced TGF-beta/Smad signaling in the early stage of diabetic nephropathy is independent of the AT1a receptor.
|
|
227.
|
2007/03
|
|
Transcription factor decoy oligonucleotide-based therapeutic strategy for renal disease.
|
|
228.
|
2007/02/20
|
|
Bilateral ureteral stenosis and duodenal perforation in a patient with dermatomyositis.
|
|
229.
|
2007/02
|
|
Amelioration of progressive renal injury by genetic manipulation of Klotho gene.
|
|
230.
|
2007/02
|
|
Isohumulones Derived from Hops Ameliorate Renal Injury via an Anti-Oxidative Effect in Dahl Salt-Sensitive Rats.
|
|
231.
|
2007
|
|
Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis.
|
|
232.
|
2007
|
|
Enhanced TGF-b/Smad signaling in the early stage of diabetic nephropathy is independent of the AT1a receptor.
|
|
233.
|
2006/09
|
|
Cardioprotective role of endogenous hydrogen peroxide during ischemia-reperfusion injury in canine coronary microcirculation in vivo
|
|
234.
|
2006/06
|
|
Endothelial dysfunction in rat adjuvant-induced arthritis: vascular superoxide production by NAD(P)H oxidase and uncoupled endothelial nitric oxide synthase.
|
|
235.
|
2006/02
|
|
[Alport syndrome: Pathogenesis, pathophysiology, and therapy].
|
|
236.
|
2006/02
|
|
[Molecular biology in regulation of kidney functions: Nitric oxide]
|
|
237.
|
2006/02
|
|
A nosocomial parvovirus B19 infection-induced transient aplastic crisis in a patient with chronic renal failure
|
|
238.
|
2006
|
|
Implication of Peritubular Capillary Loss and Altered Expression of Vascular Endothelial Growth Factor in IgA Nephropathy.
|
|
239.
|
2005/06
|
|
A case of Vogt-Koyanagi-Harada disease that developed relapsing polychondritis.
|
|
240.
|
2005/06
|
|
NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy
|
|
241.
|
2005
|
|
[Case of uremic platelet dysfunction]
|
|
242.
|
2005
|
|
Systemic nitric oxide production rate during hemodialysis and its relationship with nitric oxide-related factors
|
|
243.
|
2004/06
|
|
A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey).
|
|
244.
|
2004/03
|
|
Overexpression of Angiotensin Type 2 Receptor Ameliorates Glomerular Injury in mouse remnant kidney model
|
|
245.
|
2003/07
|
|
Glomerular cell apoptosis in human lupus nephritis
|
|
246.
|
2003/06
|
|
A novel free radical scavenger, edarabone, protects against cisplatin-induced acute renal damage in vitro and in vivo.
|
|
247.
|
2003
|
|
Implication of apoptosis in progression of renal diseases
|
|
248.
|
2001/11
|
|
Membranous nephropathy associated with hepatitis C virus infection.
|
|
249.
|
2001/06
|
|
hOGG1 polymorphism correlates with progression of IgA Nephropathy
|
|
250.
|
2001/04
|
|
Transdominant negative FGF receptors inhibit proliferation of cultured glomerular mesangial cells.
|
|
251.
|
2001/02
|
|
Renal interstitial fibrosis is reduced in angiotensin II type 1a receptor-deficient mice.
|
|
252.
|
2001
|
|
Methylprednisolone accelerates the resolution of glomerulonephritis by sensitizing mesangial cells to apoptosis.
|
|
253.
|
2000/10
|
|
Expression characteristics and relevance of sodium glucose cotranspoter-1 in mammalian renal tubulogenesis.
|
|
254.
|
2000/09
|
|
Apoptosis and extracellular matrix-cell interactions in Kidney disease.
|
|
255.
|
2000/03
|
|
Lewis(y) expression and renal tubular atrophy in IgA nephritis.
|
|
256.
|
2000/01
|
|
Caldesmon isoform associated with phenotypic modulation of mesangial cells.
|
|
257.
|
2000/01
|
|
Malignant hypertension with a rare complication of pulmonary alveolar hemorrhage
|
|
258.
|
2000/01
|
|
Synthesis and biological activities of hapalosin derivatives with modification at the C12
position.
|
|
259.
|
2000
|
|
Fatal pancreatitis associated with systemic amyloidosis in a rheumatoid arthritis patient.
|
|
260.
|
1999/12
|
|
Role of membrane-type matrix metalloproteinase 1 (MT-1-MMP), MMP-2, and its inhibitor in nephrogenesis.
|
|
261.
|
1999/11
|
|
Expression of the fibroblast growth factor receptor 1-4 genes in glomeruli in anti-Thy1.1 mesangial proliferative glomerulonephritis.
|
|
262.
|
1999/09
|
|
Tubulointerstitial nephritis antigen: an extracellular matrix protein that selectively regulates tubulogenesis vs. glomerulogenesis during mammalian renal development.
|
|
263.
|
1999/08
|
|
Cloning of rat fibrillin-2 cDNA and its role in branching morphogenesis of embryonic lung
|
|
264.
|
1999
|
|
Mechanisms for induction of apoptosis and glomerular disease.
|
|
265.
|
1999
|
|
Treatment with a Ca(2+) channel blocker, barnidipine, reduces platelet-derived growth facto B-chain mRNA in glomeruli of spontaneously hypertensive rats.
|
|
266.
|
1998/11
|
|
Concomitant use of simvastatin and cyclosporin A increases LDH in nephrotic syndrome.
|
|
267.
|
1998/11
|
|
Isolation of rat fibrillar-1 cDNA and its relevance in metanephric development.
|
|
268.
|
1998/10
|
|
Regulation of survival and death of mesangial cells by extracellular matrix.
|
|
269.
|
1998/07
|
|
Cloning of murine membrane-type-1-matrix metalloproteinase (MT-1-MMP) and its metanephric developmental regulation with respect to MMP-2 and its inhibitor
|
|
270.
|
1998/06/01
|
|
Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo
|
|
271.
|
1998/02
|
|
Antisense oligonucleotides targeting c-fos mRNA inhibit rheumatoid synovial fibroblast proliferation.
|
|
272.
|
1998/02
|
|
Expression of interleukin-8 in human glomerulonephritis.
|
|
273.
|
1998/01
|
|
Antisense oligonucleotides
|
|
274.
|
1998
|
|
Apoptosis and Scarring
|
|
275.
|
1997/10
|
|
Increased production of interleukin-10 and inflammatory cytokines in blood monocytes of hemodialysis patients.
|
|
276.
|
1997/07
|
|
Inhibition of rheumatoid synovial fibroblast proliferation by antisense oligonucleotides targeting proliferating cell nuclear antigen messenger RNA.
|
|
277.
|
1997/03
|
|
Therapeutic intervention in glomerulonephritis by oligonucleotides
|
|
278.
|
1997/02
|
|
A case of primary hyperparathyroidism accompanying multiple myeloma
|
|
279.
|
1997
|
|
Treatment of severe thrombocytopenia with intravenous immunoglobulins and corticosteroids in a patient receiving continuous ambulatory peritoneal dialysis.
|
|
280.
|
1996/11
|
|
Reactive oxygen species induce apoptosis in cultured human mesangial cells
|
|
281.
|
1996/10
|
|
Antisense oligonucleotides to proliferating cell nuclear antigen and Ki-67 inhibit human mesangial cell proliferation
|
|
282.
|
1996/07
|
|
[Role of apoptosis in renal injury]
|
|
283.
|
1996/07
|
|
Takayasu's arteritis associated with ulcerative colitis; genetic factors in this association
|
|
284.
|
1996/04
|
|
Phenotypic modulation of the mesangium reflected by contractile proteins in diabetes
|
|
285.
|
1996/03
|
|
A patient with sarcoidosis associated with recurrent urolithiasis and tubular injury caused by calcium deposition
|
|
286.
|
1996/01
|
|
Apoptosis in glomerular sclerosis
|
|
287.
|
1996
|
|
Role of apoptosis in the progression of glomerulosclerosis
|
|
288.
|
1995/10
|
|
Phenotypic changes of the mesangium in diabetic nephropathy
|
|
289.
|
1995/10
|
|
Transition of morphologic features in lupus nephritis: does steroid therapy accelerate glomerulosclerosis
|
|
290.
|
1994/11
|
|
Expression of mRNA's of cytokines and growth factors in experimental glomerulonephritis
|
|
291.
|
1994/08
|
|
Clinical significance of necrosis in lupus nephritis
|
|
292.
|
1994/07
|
|
[Effect of heparin and low-molecular-weight heparin on proliferative glomerulonephritis]
|
|
293.
|
1994/04
|
|
Localization of fibril/microfibril and basement membrane collagens in diabetic glomerulosclerosis in type 2 diabetes
|
|
294.
|
1994/02
|
|
Alteration of renal receptors for atrial natriuretic peptide and vasopressin in spontaneously hypertensive rats treated with antihypertensive diuretics.
|
|
295.
|
1994/01
|
|
Influence of hypophysectomy on renal proteoglycans and their modulation by insulin-like growth factor-I and its receptor.
|
|
296.
|
1994
|
|
In vitro micro-autoradiography of atrial natriuretic peptide in biopsy specimens from patients with renal diseases
|
|
297.
|
1994
|
|
Isolation and characterization of human cDNAs and genomic DNAs encoding alpha-4(IV) and alpha-6(IV) chains reveal the presence of a distinct subclass of collagen IV genes
|
|
298.
|
1993/08
|
|
A study on cross-reactivity of anti-DNA antibody with glycosaminoglycans
|
|
299.
|
1993/06
|
|
[A clinicopathological study of patients with immune complex type and pauci immune type rapidly progressive glomerulonephritis]
|
|
300.
|
1993
|
|
Study of glomerular permselectivity for proteins of the glomerular basement membrane using a dialyzer model
|
|
301.
|
1992/12
|
|
Nephritogenicity of anti-proteoglycan antibodies in experimental murine lupus nephritis
|
|
302.
|
1992/09
|
|
Influence of genetics on the nephritogenic potential of proteoglycans
|
|
303.
|
1992/07
|
|
Selective decreased de novo synthesis of glomerular proteoglycans under the influence of reactive oxygen species
|
|
304.
|
1992/05
|
|
Modulation of glomerular proteoglycans by insulin-like growth factor-1
|
|
305.
|
1991/07
|
|
Current status of the structural and functional basis of glomerular filtration and proteinuria
|
|
306.
|
1991/01
|
|
Effect of puromycin on metanephric differentiation: morphological, autoradiographic and biochemical studies
|
|
307.
|
1990/03
|
|
Stimulation of stromal cell growth by normal rat urothelial cell-derived epidermal growth factor
|
|
308.
|
1988/10
|
|
[A clinicopathologic study of primary malignant lymphoma of the thyroid with a report of six cases]
|
|
309.
|
1987/07
|
|
A case of postganglionic cholinergic dysautonomia
|
|
Display 5 items
|
|
Display all(309)
|
